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Abstract
Background: Omega-3 polyunsaturated fatty acids (PUFAs) have a highly anti-angiogenic effect in animal models.
However, the clinical relevance of omega-3PUFAs in human retinal pathologies remains unclear. The ARED 2 study
found no effect of omega-3 PUFA supplementation on progression of age related macular degeneration (AMD).
The aim of this study was to compare serum levels of omega-3- and omega-6 PUFAs between patients with
diabetic retinopathy (DR), AMD and retinal vein occlusion (RVO), and to identify potential confounders of serum
level measurements.
Methods: Venous blood samples were collected from 44 patients with DR, 25 with AMD, 12 with RVO and 27
controls. The lipid phase was extracted and analyzed using mass spectrometry. Retinal disease staging was done
by indirect funduscopy and FAG where appropriate. Patient demographics and medical history including current
medication and fasting state were acquired. Tukey contrasts for multiple comparisons of the mean and linear
regression analysis were used for statistical analysis.
Results: Our data revealed no significant differences in omega-6 PUFA serum levels between patients with AMD,
DR, RVO and controls (p > 0.858). Uncorrected omega-3 PUFA levels were significantly higher in patients with AMD
compared to DR but not compared to controls (p = 0.004). However, after correcting for possible confounders such
as body mass index (BMI), age, sex, fasting and use of statins, no statistically significant difference remained for
serum omega-3 PUFA levels. Fasting was identified as an independent confounder of total omega-6 PUFAs, three
individual omega-6 PUFAs and one omega-3 PUFA(p < 0.0427). Statin use was identified as an independent
confounder of α-linolenic acid (an omega-3PUFA; p = 0.0210).
Conclusion: In this pilot study with relatively low patient numbers, we report significant differences in serum levels
of omega-3PUFAs among patients with different types of retinal diseases. However, these differences were not
robust for disease specificity after correction for possible confounders in our cohort. Our results demonstrate that
serum lipid profiles need to be interpreted with caution since they are significantly altered by variables like fasting
and medication use independent from the underlying disease. Correcting for respective confounders is thus
necessary to compare serum lipid profiles in clinical studies.
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Background
Angioproliferative retinal diseases such as diabetic retin-
opathy or the wet type of age related macular degener-
ation are responsible for visual impairment among many
working age individuals and the elderly [1, 2] and lipid
mediators have been discussed as part of the pathogenetic
cascade in these disorders [3, 4].
Omega-3-polyunsatureted fatty acids (PUFAs) are major
structural lipids of retinal photoreceptor outer segment
membranes and have important structural and protective
functions in the retina [5]. The anti-inflammatory effects
of some of these omega-3PUFAs such as eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) were im-
plicated to play a protective role in AMD development
[5, 6]. In addition, it was also previously described that
omega-3PUFAs increase the retinal density of macular
pigment, which filters blue light, and has local antioxi-
dant and anti-inflammatory activities [7].
In the mouse model of oxygen-induced retinopathy
(OIR), omega-3PUFAs were found to have potent anti-
angiogenic effects on retinal neovascularization [8]. For
example, Sapieha et al. showed that the omega-3 PUFA
metabolite 4-hydroxy-docosahexaenoic acid (4-HDHA)
directly inhibits endothelial cell proliferation and sprout-
ing angiogenesis via a 5-lipoxygenase dependent pathway.
It was also shown that this effect was independent of the
anti-inflammatory properties of 4-HDHA [8]. In contrast,
the results of the age-related eye disease study 2 (AREDS2)
[9] indicate that the addition of the omega-3PUFAs DHA
and eicosapentaenoic acid (EPA) to the standard AREDS
formulation does not reduce the risk of AMD progression.
Different from AREDS2, however, Merle et al.found
serum EPA to be associated with a lower risk for neovas-
cular AMD in 290 patients from the Nutritional AMD
Treatment 2 Study (NAT2) who had neovascular AMD
in one eye and early AMD in the other eye [10]. Merle
et al. also observed in a different study with 936 elderly
patients that high plasma omega-3 PUFA levels were
associated with a reduced risk for late AMD [11]. In
contrast, Kabasawa et al. detected no difference in fatty
acid profiles of AMD patients, except for a mild associ-
ation of EPA with all types of AMD investigated [12].
These contradicting results of various AMD studies
demonstrate the need for characterization of confound-
ing parameters which might affect lipid measurements
in serum samples. This is not only important for AMD
research but also for research in other areas of retinal
disease where lipid imbalance may play a role such as
diabetic retinopathy (DR) and retinal vein occlusion
(RVO). To date, significantly less scientific data exist
for DR and RVO compared to AMD with regard to the
potential effect of lipids on disease development or
progression.
The aim of our study was therefore to identify poten-
tial confounders which may affect a perceived correl-
ation of omega3 PUFAs with the degree of AMD, DR
or RVO. In addition to omega-3 PUFAs, we also investi-
gated omega-6 PUFAs as well as monounsaturated and
saturated fatty acids.
Methods
Venous blood samples were obtained from 81 patients
with DR, AMD or RVO. In addition, samples from
27 control patients without any of the above diseases
were collected. Patients who had more than one of the
mentioned pathologies were excluded. Diabetic patients
were sub-classified in five groups: diabetes without DR
(5 patients), mild non-proliferative DR (6 patients),
moderate non-proliferative DR (14 patients), severe
non-proliferative DR (5 patients) and proliferative DR
(15 patients). The grading was done according to the
EDTRS–guidelines [13]. Patients with AMD were
sub-grouped in four different categories: early dry
AMD (4 patients), active wet AMD (12 patients), scarred
wet AMD (3 patients) and geographic atrophy (GA; 6
patients). Patients with retinal vein occlusion were distin-
guished as suffering from branch retinal vein occlusion
(BRVO, 7 patients), or central retinal vein occlusion
(CRVO, 5 patients).
Additional clinical data were acquired by indirect fun-
doscopy and FAG where appropriate. For all patients
additional information was gathered including medical
history, current and past medication (including vitamin
supplementation), state of fasting and body mass index
(BMI).
The study was registered with the Ethics Committee at
the University Hospital Freiburg. After obtaining written
informed consent, one serum sample per patient was
acquired by venous blood draw and stored at −80 °C
until being used for lipid extraction. Lipid extraction was
performed by the Department of Clinical Chemistry at
the University of Freiburg as previously described at a
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temperature of 4 ° C in a two-step procedure [14].
100 μl of serum sample were mixed with 100 μl methyl-
pentadecanoate 5 mg/l as internal lipid standard mixture
(analytical standard grade, Sigma, Taufkirchen, Germany).
Samples were extracted with 990 μl chloroform/methanol
(17:1, V/V) for 120 min. The lower organic 17:1 lipid
phase extract was collected. The remaining aqueous sam-
ple material was re-extracted with 990 μl chloroform/
methanol (2:1, V/V) for 120 min. Again, the lower organic
2:1 lipid phase extract was collected. Combined organic
phases were then evaporated in vacuum. The dried lipid
extracts were dissolved in 70 μl chloroform and 30 μl of
trimethylsulfonium hydroxid (0.25 M in methanol, Sigma
Aldrich) were added. To yield respective fatty acid methyl
esters, the mixture was stirred for 30 min at room
temperature [15]. Fatty acid methyl esters were analyzed
by GC-MS on an Agilent GC 6890/MS 5973 platform
(Agilent Technologies Deutschland GmbH, Böblingen
Germany). Helium (5.0) was used as carrier gas, injection
volume was 1 μl and flowrate was 0.4 ml/min on a SP-
2380 capillary column (Sigma). Initial temperature was
100 °C, rising with 6 °C/min to a final temperature of
220 °C, which was kept for 10 min. Mass spectra were re-
corded in fullscan mode from m/z 45 to 800. Total ion
chromatograms (TICs) and fragmentation patterns were
acquired by G1701DA GC/MSD Chemstation software.
Fatty acid methyl esters were identified by retention time
and characteristic mass-to-charge ratios compared to a
standard mass chromatogram in the NIST (National Insti-
tute of Standards and Technology) mass spectral library.
Peak areas were quantitated manually for each identified
fatty acid methyl ester. Results for respective fatty acids
are presented as percentage of total fatty acid content per
sample. Statistical analysis was performed using R with
the following packages: plyr, reshape, car, Hmisc, ggplot2
and multcomp. We applied ANOVA, Tukey contrasts for
between-group comparisons and linear regression for
inference analyses.
Results
Our initial analysis of native sample readings without cor-
rection for potential confounders suggested significantly
higher omega-3PUFA levels in patients with AMD com-
pared to patients with DR (p = 0.00405; Table 1a). For
omega-6 PUFA levels, there was no significant differ-
ence between patients with AMD, DR, RVO and con-
trols (p > 0,858; Table 1b).
When analyzing not only the broad disease categories
AMD, DR and RVO, but also disease subgroups, there
were no significant differences for omega-3 or omega-6
PUFAs. Two exemplary comparisons across disease sub-
groups are shown in Fig. 1 for DHA, a major omega-3
fatty acid and arachidonic acid (AA), a major omega-6
fatty acid. Similar patterns without apparent differences
across disease subgroups were observed for other indi-
vidual fatty acids.
Since the primary objective of this study was to de-
termine whether independent variables may act as con-
founders of PUFA serum measurements, we analyzed
our data set using a linear regression model correcting
for patient age and sex, body mass index (BMI), the
use of oral statin medication and the state of fasting
(defined as at least six hours fasting prior to blood
sampling). The results shown in Table 2 demonstrate
that fasting state is an independent confounder for
omega-6, but not omega-3 PUFA measurements. More
importantly, the data also demonstrate that none of
the three disease entities (DR, RVO, AMD) acts as an
independent variable on total omega-3 or omega-6
PUFA levels in our cohort when using a linear regres-
sion model. A full list of fatty acids analyzed can be
found as Additional file 1.
Next, we investigated whether individual fatty acids
were significantly affected by individual patient vari-
ables. Table 3 demonstrates that the fasting state of a
patient acts as an independent confounder of total
omega-6PUFAs, three individual omega-6 PUFAs and
one omega-3 PUFA (p < 0.0427). Statin medication was
identified as an independent confounder of α-linolenic
acid (an omega-3 PUFA; p = 0.0210). Interestingly, pa-
tient age and BMI were no independent confounders of
serum lipid measurements. The small patient number
especially in the RVO subgroup has to be considered
when interpreting the results of this pilot study.
Table 1 Serum omega-3 (A) and omega-6 (B) PUFA levels in
patients with different retinal diseases
Estimate std. error t value Pr (>|t|)
A. omega-3 PUFAs
AMD vs Control 0.48 0.25 1.92 0.222
DR vs Control −0.28 0.22 −1.26 0.585
RVO vs Control −0.13 0.31 −0.41 0.976
DR vs AMD −0.76 0.22 −3.47 0.004**
RVO vs AMD −0.61 0.31 −1.98 0.199
RVO vs DR 0.15 0.29 0.53 0.950
B. omega-6 PUFAs
AMD vs Control 0.59 1.60 0.37 0.983
DR vs Control 1.11 1.42 0.79 0.858
RVO vs Control 0.64 2.02 0.32 0.988
DR vs AMD 0.52 1.44 0.37 0.983
RVO vs AMD 0.06 2.03 0.03 1.000
RVO vs DR −0.47 1.90 −0.25 0.994
The table displays group comparisons without correction for potential
confounders. p-values are shown in the right column and were calculated
using ANOVA with Tukey contrasts correcting for multiple testing
**signifies p-values < 0.01
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Discussion
Numerous clinical studies have investigated a possible
protective effect of omega-3PUFA supplementation on
the progression of AMD. These studies yielded variable
and contradicting results [9, 10, 16, 17]. The AREDS2
clinical trial, for example, did not find a beneficial effect
for omega-3 PUFA supplementation on disease progres-
sion [9]. Other studies, in contrast, observed beneficial
associations of certain omega-3 PUFA subtypes, such as
EPA with AMD risk [10]. For DR and RVO there is sig-
nificantly less literature compared to AMD regarding a
potential association of omega-3 PUFAs with disease
stage or progression. In this study, we describe import-
ant confounders that may contribute to contradicting
results in studies correlating serum lipid levels and eye
disease. In addition, our results add valuable data on the
less studied disease entities DR and RVO with regard to
systemic lipid profiles.
Despite the small sample size of this pilot study, our
data clearly suggest that serum lipid levels cannot be used
for clinical ophthalmological studies without vigorous cor-
rection for potential confounders. The most important
confounder is patient fasting state, which affects various
unsaturated and saturated fatty acid levels. Most of the
existing AMD studies have corrected for potential con-
founders and report fasting status in their publications.
For example, the study by Merle et al. which identified
EPA as a risk variable for neovascular AMD did correct
for a list of potential confounders including fasting state
of the patient [10]. It has to be kept in mind when
interpreting lipid studies in general, that not only fast-
ing state but dietary habits in general differ between
populations and can potentially impact study results. A
meta-analysis published in 2008, for example, postu-
lates reduced risk for AMD in patients with high diet-
ary intake of Omega-3 PUFAs [18]. For a Japanese
AMD population, in contrast, Kabasawa et al. reported
no associations with serum omega-3 and omega-6
PUFA levels [12]. Since fish intake in Japan is generally
among the highest in the world [19, 20], the effect of
Fig. 1 Serum patterns for two exemplary PUFAs for patients with retinal disease and controls. Top row shows serum levels of docosahexaenoic
acid (DHA, 22:6), an omega-3 fatty acid, bottom row shows the same for arachidonic acid (AA, 20:4), an omega-6 fatty acid. In this analysis, patients
with diabetic retinopathy (DR), retinal vein occlusion (RVO) and age-related macular degeneration (AMD) were subdivided into their respective
subgroups as indicated. No significant differences were detected across groups. The same is true for all other PUFAs investigated (not shown).
Mean and standard deviations of relative fatty acid compositions (all lipid classes) are given
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omega-3 PUFAs on AMD could potentially have been
masked in this population. In addition, changes in
serum fatty acid profiles do not necessarily translate
into changes in retinal fatty acid profiles.
The second important finding of our study is that, in
our cohort, total omega-3 or omega-6 PUFA levels were
not independently associated with the presence of AMD.
Different from our study, Merle et al. found associations
between AMD and EPA, an omega-3 PUFA [10]. While
Merle et al. only investigated patients with neovascular
AMD, our study comprised samples from patients with
all forms and stages of AMD. The subset of neovascular
AMD patients might thus have been too small to pick
up potential differences in AMD levels. In contrast to
AMD, there is significantly less data available correlating
omega-3 and omega-6 PUFA serum levels with the de-
gree of DR or RVO. With regard to RVO, this study is
to our knowledge the first to investigate possible associa-
tions with serum lipid profiles. In our relatively small
patient cohort, we did not find associations of omega-3
or −6 PUFA levels and the presence of RVO. Similarly,
DR was not associated with omega-3 or −6 PUFA levels
in our cohort. This is different from saturated fatty acids,
for which a positive association with the presence and
severity of DR was described [21].
We would like to point out that larger patient num-
bers would be necessary in order to more reliably inves-
tigate clinically relevant differences between patient
groups. The main purpose of this manuscript, however,
was to identify and flag potent confounders of lipid
serum measurement that have to be accounted for when
performing these studies. Even with our low patient
numbers we were able to identify such confounders – an
indication of their potency in affecting results from
serum lipid measurements. In this respect, our current
manuscript has to be viewed as preparatory work for
larger studies by providing important information on
methodological aspects of serum lipid measurements
that have to be accounted for in larger clinical trials.
Conclusions
In summary, our data together with the discussed litera-
ture emphasize the need for (i) correction for identified
confounders of serum lipid profile measurements and
(ii) interpretation of lipid profiles in light not only of the
disease entity studied but also the underlying patient
population. One limitation of our study is the relatively
low sample number. Larger patient numbers are thus
needed to obtain a full understanding of all factors influ-
encing serum lipid measurements.
Additional file
Additional file 1: This file contains a list of all fatty acids analyzed for this
study. (DOC 41 kb)
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Table 2 Serum omega-3 (A) and omega-6 (B) PUFA levels
corrected for potential confounders
Estimate std. error t value Pr (>|t|)
A. omega-3 PUFAs
BMI 0.01 0.02 0.38 0.706
Statin use 0.03 0.25 0.12 0.905
Fasting −0.37 0.29 −1.29 0.201
Age 0.01 0.01 0.55 0.582
Sex −0.10 0.21 −0.48 0.635
AMD 0.45 0.31 1.43 0.155
DR −0.35 0.27 −1.29 0.199
RVO −0.23 0.35 −0.65 0.516
B. omega-6 PUFAs
BMI −0.19 0.12 −1.55 0.125
Statin use −2.16 1.39 −1.56 0.123
Fasting −5.67 1.63 −3.49 0.001***
Age 0.08 0.04 1.90 0.061
Sex 0.79 1.15 0.68 0.496
AMD −1.82 1.75 −1.04 0.300
DR 0.37 1.45 0.26 0.798
RVO −2.22 1.97 −1.19 0.262
When serum lipid measurements were corrected for the possible confounders
body mass index (BMI), statin use, fasting, age and sex of the patient, none of
the retinal disease categories acted as an independent variable affecting
serum lipid levels. Fasting, in contrast, was identified as an independent
variable that significantly affects serum omega-6 PUFA measurements.
***signifies p-values ≤ 0.001
Table 3 Independent patient variables affecting fatty acid
measurements
Variable Fatty acid affected by independent variable
BMI –
Statin use 18:3 (Ώ-3-PUFA)
Fasting 14:00, 18:2 (Ώ-6-PUFA), α18:3 (Ώ-3-PUFA),




Multiple regression analysis for individual fatty acids identified several fatty
acids whose serum levels were significantly associated with differences in a
patient’s baseline variables. Fasting state was the most signficiant variable,
independently affecting various saturated and unsaturated fatty acid
measurements. Statin use and patient sex each affected one of the fatty acids
investigated. Patient age and body mass index (BMI) were no independent
variables of serum fatty acid measurements in our cohort. Affected fatty acids
in this table are noted according to the carboxyl reference system
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